Gland B2B Business Model and Growth Strategy

Key Strengths 18 6 Experienced and Qualified Management Team 5 Track Record of Growth and Profitability from a Diversified Revenue Base with Healthy Cash Flows 4 Extensive Portfolio of Complex Products Supported by Internal R&D and Regulatory Capabilities GLAND GLAND PHARMA LIMITED Note: (1) 3 API facilities provide in-house manufacturing capabilities for critical APIs. 32 ANDAs covering key products are supported by in-house APIs Injectables: One of the Fastest Growing and Largest Segment 1 Extensive and Vertically Integrated Injectables Manufacturing Capabilities (1) Diversified B2B-led Model Across Markets, Complemented by Targeted B2C Model in India 3 2 GLAND

View entire presentation